Paperpal Prime Logo

Cardiovascular Therapeutics : Impact Factor & More

eISSN: 1755-5922pISSN: 1755-5914
JournalOpen Access

Key Metrics

CiteScore
4.6
H-Index
52
Impact Factor
< 5
SJR
Q2Pharmacology
SNIP
0.87
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Cardiovascular Therapeutics

Cardiovascular Therapeutics Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher WILEY-HINDAWI
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2000
Publication Time19
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2008
Website URLVisit website
Publication Details
Other chargesVisit website
PlagiarismVisit website
Publication Time 19
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY
OA statementVisit website
View less

Planning to publish in Cardiovascular Therapeutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Cardiovascular Therapeutics

Correlation Between Apolipoprotein B and Severity of Coronary Artery Stenosis in Individuals Aged 45 and Above: A Cross\u2010Sectional Study
  • 5 Aug 2026
  • Cardiovascular Therapeutics
Analysis of the Correlation Between Helper T\u2010Lymphocyte Subsets and Atrial Fibrillation: An Observational and Mendelian Randomization Study
  • 4 Aug 2026
  • Cardiovascular Therapeutics
The Prognostic Value of Different Patterns of Neoatherosclerosis and Treatment Modality in Patients With Coronary In\u2010Stent Restenosis
  • 17 Jun 2026
  • Cardiovascular Therapeutics
Baseline Ejection Fraction as a Modifier of Beta\u2010Blocker Therapeutic Effects in Post\u2010Acute Coronary Syndrome Patients With Non\u2010Reduced Ejection Fraction: A Systematic Review and Meta\u2010Analysis
  • 17 Jun 2026
  • Cardiovascular Therapeutics
Exploring the Other Side of Medication: A Patient Interview Study on Anti\u2010PCSK9 Monoclonal Antibodies
  • 16 Jun 2026
  • Cardiovascular Therapeutics
Lycorine Attenuates Cardiac Fibrosis Through the Regulation of PYK2 Expression and Activity
  • 16 Jun 2026
  • Cardiovascular Therapeutics
Correlation Between Apolipoprotein B and Severity of Coronary Artery Stenosis in Individuals Aged 45 and Above: A Cross\u2010Sectional Study
  • 5 Aug 2026
  • Cardiovascular Therapeutics
Analysis of the Correlation Between Helper T\u2010Lymphocyte Subsets and Atrial Fibrillation: An Observational and Mendelian Randomization Study
  • 4 Aug 2026
  • Cardiovascular Therapeutics
The Prognostic Value of Different Patterns of Neoatherosclerosis and Treatment Modality in Patients With Coronary In\u2010Stent Restenosis
  • 17 Jun 2026
  • Cardiovascular Therapeutics
Baseline Ejection Fraction as a Modifier of Beta\u2010Blocker Therapeutic Effects in Post\u2010Acute Coronary Syndrome Patients With Non\u2010Reduced Ejection Fraction: A Systematic Review and Meta\u2010Analysis
  • 17 Jun 2026
  • Cardiovascular Therapeutics
Exploring the Other Side of Medication: A Patient Interview Study on Anti\u2010PCSK9 Monoclonal Antibodies
  • 16 Jun 2026
  • Cardiovascular Therapeutics
Lycorine Attenuates Cardiac Fibrosis Through the Regulation of PYK2 Expression and Activity
  • 16 Jun 2026
  • Cardiovascular Therapeutics

FAQs on Cardiovascular Therapeutics